Old and new anticoagulant agents for the prevention and treatment of patients with ischemic stroke

Cerebrovascular Diseases

Volumn 27, Issue SUPPL. 1, 2009, Pages 111-119

  Martí Fàbregas, Joan ^a   Mateo, José ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Anticoagulants; Atrial fibrillation; Heparin; Ischemic stroke; Vitamin K antagonists; Warfarin; Ximelagatran

Indexed keywords

ACETYLSALICYLIC ACID; ANCROD; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; COUMARIN DERIVATIVE; DABIGATRAN ETEXILATE; DU 176B; FONDAPARINUX; HEPARIN; IDRAPARINUX; PLACEBO; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN; YM 150;

ACUTE HEART INFARCTION; ANTICOAGULATION; BLEEDING; BLOOD VESSEL INJURY; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; EMBOLISM; EMBOLISM PREVENTION; ENDOTHELIUM INJURY; ENZYME INHIBITION; FIBRIN FORMATION; FOLLOW UP; FOOD DRUG INTERACTION; HEART ATRIUM FIBRILLATION; HUMAN; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; MITRAL VALVE PROSTHESIS; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; POLYPHARMACY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTHROMBIN TIME; RHEUMATIC DISEASE; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT; SINGLE DRUG DOSE; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM; THROMBOGENESIS; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION; BRAIN ISCHEMIA; FACTOR XA; HUMANS; PRIMARY PREVENTION; RISK ASSESSMENT; SECONDARY PREVENTION; STROKE; THROMBIN; TREATMENT OUTCOME; VITAMIN K;

EID: 64149123175     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000200448     Document Type: Conference Paper

References (45)

1. Go AS, Hylek EM, Borowsky LH, Phillips K A, Selby J V, Singer DE: Wa rfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in at rial f ibri llation (ATRIA) study. Ann Intern Med 1999; 131:927-934.
2. Fuentes B, Díez Tejedor E, Gil-Núñez A, Gil-Peralta A, Matías-Guiu J, on behalf of the Cerebrovascular Diseases Study Group from the Spanish Society of Neurology: Guía para el tratamiento preventivo de la isquemia cerebral; in Díez-Tejedor E (ed): Guía para el Diagnóstico y Tratamiento del Ictus. Barcelona, Prous Science, 2006, pp 133-183.
3. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE: Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349:1019-1026.
4. Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, Glahn J, Brandt T, Hacke W, Diener HC: Risk factors, outcome, a nd treat ment in subt y pes of ischemic stroke: the German stroke data bank. Stroke 2001;32:2559-2566.
5. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL: ACC/AHA/ESC 2006 Guidelines for the Ma na gement of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e257-e35 4.
6. Reynolds MW, Fahrbach K, Hauch O, Wygant G, Estok R, Cella C, Nalysnyk L: Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest 2004; 126:1938-1945.
7. Hylek EM, Skates SJ, Sheehan MA, Singer DE: An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335: 540-546.
8. Hart RG, Benavente O, Pearce LA: Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis. Cerebrovasc Dis 1999; 9:215-217.
9. Shireman TI, Howard PA, Kresowik TF, Ellerbeck EF: Combined anticoagulant-anti-platelet use and major bleeding events in elderly atrial fibrillation patients. Stroke 2004;35: 2362-2367.
10. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinica l trial. Lancet 1996; 348: 633-638.
11. Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, Jensvold NG, Selby J V, Singer DE: Anticoagulation therapy for stroke prevention in atrial fibrillation: how wel l do randomized trials translate into clinical pract ice? JAMA 20 03; 29 0 : 2685-2692.
12. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Murray E: Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370:493-503.
13. Hart RG, Pearce LA, Aguilar MI: Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonva lvu lar atria lfibrillation. Ann Intern Med 2007; 146:857-867.
14. van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, Koudstaal PJ, Chang Y, Hellemons B: Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 20 02; 288: 24 41-244 8.
15. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S: Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 19 03-1912.
16. Bousser MG, Bouthier J, Buller HR, Cohen AT, Crijns H, Davidson BL, Halperin J, Hankey G, Levy S, Pengo V, Prandoni P, Prins MH, Tomkowski W, Thorp-Pedersen C, Wyse DG: Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, noninferiority trial. Lancet 2008;371:315-321.
17. Olsson SB: Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003;362:1691-1698.
18. Albers GW, Diener HC, Frison L, Grind M, Nevinson M, Partridge S, Halperin JL, Horrow J, Olsson SB, Petersen P, Vahanian A: Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005; 293: 690-698.
19. Diener HC: Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies. Cerebrovasc Dis 2006; 21:279-293.
20. Ezekowitz MD, Reilly PA, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-Azad K, Pedersen KE, Lionetti DA, Stangier J, Wallentin L: Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007;100:1419-1426.
21. Immediate anticoagulation of embolic stroke: a randomized trial. Cerebral Embolism Study Group. Stroke 1983;14:668-676.
22. Hart RG, Palacio S, Pearce LA: Atrial fibrillation, stroke, and acute antithrombotic therapy: analysis of randomized clinical trials. Stroke 2002;33:2722-2727.
23. Saxena R, Lewis S, Berge E, Sandercock PA, Koudstaal PJ: Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial. Stroke 2001;32:2333-2337.
24. Gubit z G , Sandercock P, Counsell C: Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev 2004:CD000024.
25. Paciaroni M, Agnelli G, Micheli S, Caso V: Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a metaanalysis of randomized controlled trials. Stroke 2007; 38:423-430.
26. Coull BM, Williams LS, Goldstein LB, Meschia JF, Heitzman D, Chaturvedi S, Johnston KC, Starkman S, Morgenstern LB, Wilterdink JL, Levine SR, Saver JL: Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). Stroke 2002; 33:1934-1942.
27. The European Stroke Organisation (ESO) Executive Committee and the ESO Writing Committee: Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008. Cerebrovasc Dis 2008; 25:457-507.
28. Chamorro A, Vila N, Saiz A, Alday M, Tolosa E: Early anticoagulation after large cerebral embolic infarction: a safety study. Neurology 1995; 45:861-865.
29. Chamorro A, Vila N, Ascaso C, Blanc R: Heparin in acute stroke with atrial fibrillation: clinical relevance of very early treatment. Arch Neurol 1999;56:1098-1102.
30. Chamorro A, Busse O, Obach V, Toni D, Sandercock P, Reverter JC, Cervera A, Torres F, Davalos A: The rapid anticoagulation prevents ischemic damage study in acute stroke - final results from the writing committee. Cerebrovasc Dis 2005;19:402-404.
31. Camerlingo M, Salvi P, Belloni G, Gamba T, Cesana BM, Mamoli A: Intravenous heparin started within the first 3 h after onset of symptoms as a treatment for acute nonlacunar hemispheric cerebral infarctions. Stroke 2005; 36: 2415-2420.
32. Caplan LR: When should heparin be given to patients with atrial fibrillation-related embolic brain infarcts? Arch Neurol 1999; 56:1059-1060.
33. Sherman DG, Atkinson RP, Chippendale T, Levin KA, Ng K, Futrell N, Hsu CY, Levy DE: Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial. JAMA 2000; 283:2395-2403.
34. Hennerici MG, Kay R, Bogousslavsky J, Lenzi GL, Verstraete M, Orgogozo JM: Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial. Lancet 2006; 368: 18 7 1-18 78.
35. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993;342:1255-1262.
36. Group TEAFTs: Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. The European Atrial Fibrillation Trial Study Group. N Engl J Med 1995;333:5-10.
37. Smith EE, Rosand J, Knudsen KA, Hylek EM, Greenberg SM: Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke. Neurology 2002; 59:193-197.
38. Gorter JW: Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups. Neurology 1999; 53:1319-1327.
39. Akins PT, Feldman HA, Zoble RG, Newman D, Spitzer SG, Diener HC, Albers GW: Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials. Stroke 2007; 38:874-880.
40. Hart RG, Tonarelli SB, Pearce LA: Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke 2005; 36: 1588-1593.
41. Algra A: Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol 2007; 6:115-124.
42. Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Kasner SE, Benesch CG, Sila CA, Jovin TG, Romano JG: Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005;352:1305-1316.
43. Marti-Fabregas J, Cocho D, Marti-Vilalta JL, Gich I, Belvis R, Bravo Y, Millan M, Castellanos M, Rodriguez-Campello A, Egido J, Geffner D, Gil-Nunez A, Marta J, Navarro R, Obach V, Palomeras E: Aspirin or anticoagulants in stenosis of the middle cerebral artery: a randomized trial. Cerebrovasc Dis 2006;22:162-169.
44. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams HP Jr, Jackson CM, Pullicino P: A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;345:1444-1451.
45. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. Ann Neurol 1997;42:857-865.